Fundraising FoxLmito
1 known investors
Find your way into Lmito
Each arrow is one introduction. Sign up to fill in the first one.
Ask Andreas Muehler to introduce you to Wheeseong Lee
You →Andreas · together at Berlex (currently Bayer Schering Pharma), Richmond, CA →Wheeseong
Sign up to find every way you can get introduced to Lmito
- Your email: who you already know at Lmito, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Lmito team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Lmito Therapeutics is a drug discovery company focused on mitochondrial and cell metabolism, targeting areas such as immunology, neuroimmunology, and immuno-oncology. It operates using a fully integrated pharmaceutical network (FIPNet) business model.
Also known as Lmito Therapeutics · Lmito Therapeutics Inc.
Founders & leadership
Investors · 1
Company profile
researched Aug 2026Lmito Therapeutics is a clinical-stage pharmaceutical company developing therapies for autoinflammatory and autoimmune disorders and fibrotic diseases by reprogramming mitochondrial and cellular metabolism. Its stated approach is to target metabolically overactivated cells within pathogenic microenvironments and selectively alter their metabolism, rather than broadly suppressing the immune system. Indications named by the company span autoinflammatory/autoimmune disease (inflammatory bowel disease, rheumatoid arthritis, interstitial lung disease, ankylosing spondylitis), pro-fibrotic disorders (idiopathic pulmonary fibrosis, fibrostenosis, progressive fibrosing interstitial lung disease) and neuroinflammatory/neurodegenerative disease (multiple sclerosis, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease).
Research is organized around three therapeutic areas. In immunometabolism, the company's compounds are described as modulating the metabolism of overactivated immune cells to modify their function and mitigate inflammation without the immunosuppression-related adverse effects such as infection. In neurological disorders, the work addresses overactivated proinflammatory reactive astrocytes and the polarization of M1-like proinflammatory microglia toward an M2-like anti-inflammatory phenotype. In fibrosis, the company targets unregulated glycolysis in activated fibroblasts and myofibroblasts, aiming to limit excess extracellular matrix production and related processes such as epithelial-mesenchymal transition and inflammatory responses through metabolic reprogramming.
Founding story
Founder and CEO Wheeseong Lee has 25 years of experience in drug development in oncology and inflammation, with research focused on mitochondria and cell metabolism as related to immunology, neuroimmunology and immuno-oncology. He holds a PhD in organic chemistry from the University of Illinois at Urbana-Champaign and conducted postdoctoral research at the California Institute of Technology. COO Eunju Lee has over 20 years of experience in clinical development and corporate strategy at large and small pharmaceutical companies, and holds an RN from Catholic University and an MBA from Sogang University.
Business model
The company states it will adopt a fully integrated pharmaceutical network (FIPNet) as its strategic business model, drawing on external partners alongside internal research. It has licensed out a drug candidate and has received national grant funding from the Korea Drug Development Fund.
Traction
The company reports closing a Series A round in September 2020, winning a national grant from the KDDF in December 2021, and receiving approval of a clinical study for an inflammatory bowel disease drug candidate in February 2022. It also reports having licensed out a drug candidate in January 2020.
Latest developments
The most recent company news item, dated February 2022, reports approval of a clinical study for its inflammatory bowel disease drug candidate.
▸Full profile — market position, technology, go-to-market, geography
Market position
Positions itself as a clinical-stage company applying metabolic reprogramming of mitochondrial and cellular metabolism across immunology, neuroimmunology, immuno-fibrosis and immuno-oncology.
Technology
Small-molecule compounds that modulate cell and mitochondrial metabolism (immunometabolism), including modulation of overactivated immune cells, reactive astrocytes and microglia polarization, and glycolysis in activated fibroblasts and myofibroblasts. The company has also reported developing compounds through artificial-intelligence-based drug discovery.
Go-to-market
Patients with autoinflammatory and autoimmune disorders, pro-fibrotic diseases and neuroinflammatory/neurodegenerative conditions, addressed through pharmaceutical partners and licensees.
Geography
Company news coverage is attributed to Korean outlets including BioSpectator and the Korea University Newsroom, and grant funding comes from the Korea Drug Development Fund.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 5
launches, deals, and filingsCompany news item reporting that Lmito received approval of a clinical study for its IBD drug, as reported by BioSpectator.
Company news item reporting that Lmito won a national grant from the Korea Drug Development Fund (KDDF), as reported by BioSpectator.
Company news item reporting that Lmito successfully closed its Series A funding round, as reported by BioSpectator. No amount disclosed.
Company news item reporting that Lmito developed compounds through artificial-intelligence-based drug discovery, as reported by the Korea University Newsroom.
Company news item reporting that Lmito licensed out a drug candidate; the item is attributed to Samyang Biopharm.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Lmitolmito.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Lmito do?
- Clinical-stage pharmaceutical company developing therapies that reprogram mitochondrial and cell metabolism.
- Who founded Lmito?
- Lmito was founded by Wheeseong Lee.
- Who are Lmito's investors?
- Lmito's investors include Kiwoom Investment.